Biểu đồ giá cổ phiếu IFRX
IFRX Thu nhập
InflaRx NV
$2.5
-3.1%
$-0.08
Khi đóng cửa: May 11, 16:00:00 GMT-4
$2.4
-4%
$-0.1
Phiên trước giờ: May 12, 07:34:05 GMT-4
Quay lại
InflaRx NV (IFRX) Thu nhập
Thống kê chính
Giá đóng cửa trước
$2.58
Giá mở cửa
$2.55
Phạm vi ngày
$2.4 - $2.72
Phạm vi 52 tuần
$0.7113 - $2.4
Khối lượng
3.9M
Khối lượng trung bình
618.8K
Tỷ suất cổ tức
--
EPS (TTM)
-0.61
Vốn hóa thị trường
$173.4M
IFRX là gì?
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
